Kaposi’s sarcoma Market Insights and Market Report 2030 1

A detailed review of historical and forecasted Kaposi’s sarcoma market is included in the report, covering drug outreach in the 7MM countries. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Kaposi’s sarcoma market.


Kaposi’s sarcoma Overview

Kaposi’s sarcoma (KS) is a multicentric vascular tumor originating in the endothelial cells that line blood vessels and lymphatic vessels. KS is caused when tiny blood vessels develop below the surface of skin, in the mouth, nose, eyes, or other parts of the body, such as the lymph nodes or lungs. Individuals with weak immune system, especially HIV patients, have high risk of Kaposi’s sarcoma. The lesions of Kaposi’s sarcoma typically appear as painless purplish spots on the feet, legs, face, genital area, mouth or lymph nodes. In severe Kaposi’s sarcoma, lesions may develop in the lungs and digestive tract.


Download Sample Report- Kaposi’s sarcoma Market Report


Some of the key highlights of Kaposi’s sarcoma market report

  • Age-adjusted KS incidence rates in the United States decreased from 1.44/100,000 to 0.95/100,000 between 2000 and 2014.
  • KS incidence was 87% higher in men than women, over twofold greater in non-whites than whites, and two-fold higher in non‐US citizens than US citizens.
  • KS incidence increased with age at transplant and decreased sharply with time since transplant, so that the highest incidence occurred within 1 year of transplant.


Kaposi’s sarcoma Market: Companies

  • Vasgene Therapeutics, Inc
  • Bristol-Myers Squibb
  • And many others


Kaposi’s sarcoma Market: Symptoms

The symptoms of Kaposi’s Sarcoma include trouble in eating and swallowing, vomiting, upset stomach, belly pain from blockages and bleeding, swelling in arms legs and face, shortness of breath, and serious coughing. Other symptoms may include fatigue, night sweats, and weight loss. Kaposi’s sarcoma is more common in men than in women.


Kaposi’s sarcoma Market: Treatment

The treatment of Kaposi’s Sarcoma consists of antiretroviral therapies, radiation therapy, chemotherapy drugs such as Doxorubicin (Adriamycin, Doxil), Paclitaxel (Taxol), Vinblastine (Velban), etc. and several biologic therapies to boost immune system.


Kaposi’s sarcoma Market Insights

The main forms of treatment for Kaposi’s Sarcoma are Antiretroviral Therapy, Surgery, Photodynamic Therapy, Radiation Therapy, therapies using medications such as Chemotherapy, Topical medications, Targeted Therapy and Immunotherapy.


Request sample report- Kaposi’s sarcoma Market Insights


Table of content

1. Key Insights

2. Executive Summary of Kaposi’s sarcoma

3. Competitive Intelligence Analysis for Kaposi’s sarcoma

4. Kaposi’s Sarcoma: Market Overview at a Glance

5. Kaposi’s Sarcoma: Disease Background and Overview

6. Patient Journey

7. Kaposi’s Sarcoma Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Kaposi’s sarcoma Treatment

11. Marketed Products

12. Emerging Therapies

13. Kaposi’s Sarcoma: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Kaposi’s sarcoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


About DelveInsight

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.


Contact Us



Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Leave a Reply

Your email address will not be published.